CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has appointed Phil Pereira Director of Manufacturing. Mr. Pereira will be responsible for overseeing scale-up, qualification and compliance efforts in the manufacture of InVivo’s lead product candidate, a novel, biocompatible polymer scaffolding device, at the company’s recently opened manufacturing and development facility in Medford, Massachusetts. Mr. Pereira will report to Frank Reynolds, Chief Executive Officer of InVivo Therapeutics.
“Phil brings valuable cGMP manufacturing experience to the team at an important time in our corporate development,” said Frank Reynolds, CEO of InVivo Therapeutics. “We look forward to his contributions in ensuring that the highest standards are met throughout the scale-up of our manufacturing capabilities and ahead of the first clinical study using our biocompatible polymer scaffolding device.”
"InVivo is characterized by its strong leadership, focused strategy and this extraordinary potential to create a new paradigm for the treatment of SCI," said Mr. Pereira. "Its technology platform is formed around unique polymers co-invented by Dr. Robert Langer, a scientist world-renowned for discoveries using such materials. I look forward to working with the management team at InVivo in developing their world-class manufacturing capability."
Prior to joining InVivo Therapeutics, Mr. Pereira served for seven years as Senior Manufacturing/Product Development Engineer at Intrinsic Therapeutics. In this position, he was responsible for overseeing and scaling up cGMP (current good manufacturing practice) manufacturing activities for the company’s various products, including its polymer- and biomaterials-based products. Prior to Intrinsic Therapeutics, Mr. Pereira was at NMT Medical where he was responsible for the development and manufacturing of implantable devices to treat certain heart defects. Mr. Pereira’s experience includes process design, qualification and scale-up, manufacturing engineering, and regulatory compliance in research and development, pilot and commercial manufacturing cGMP medical device environments. He holds a Bachelor of Science in Mechanical Engineering Technology from Northeastern University and several certifications in manufacturing and engineering including ISO 9001, ISO EN13485 and 21 CFR Part 820-Quality Systems.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital in Boston.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.